HC Wainwright Issues Optimistic Forecast for GANX Earnings

Gain Therapeutics, Inc. (NASDAQ:GANX) – Stock analysts at HC Wainwright lifted their Q2 2025 EPS estimates for Gain Therapeutics in a note issued to investors on Monday, May 19th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.16) per share for the quarter, up from their prior estimate of ($0.19). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.00) per share. HC Wainwright also issued estimates for Gain Therapeutics’ Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.59) EPS, Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.13) EPS and FY2026 earnings at ($0.56) EPS.

GANX has been the topic of a number of other research reports. Chardan Capital reiterated a “buy” rating and set a $6.00 price target on shares of Gain Therapeutics in a report on Friday, March 28th. Scotiabank initiated coverage on shares of Gain Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $12.00 price target on the stock. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $8.20.

Gain Therapeutics Price Performance

Shares of GANX opened at $1.91 on Wednesday. The stock has a market cap of $56.46 million, a PE ratio of -1.74 and a beta of 0.17. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.99 and a current ratio of 2.99. Gain Therapeutics has a fifty-two week low of $0.89 and a fifty-two week high of $3.19. The firm’s 50-day simple moving average is $1.93 and its two-hundred day simple moving average is $2.00.

Gain Therapeutics (NASDAQ:GANX) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.16) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.16).

Institutional Investors Weigh In On Gain Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Benedict Financial Advisors Inc. bought a new position in Gain Therapeutics during the fourth quarter valued at approximately $35,000. Sprott Inc. bought a new position in Gain Therapeutics during the fourth quarter valued at approximately $30,000. Jones Financial Companies Lllp lifted its position in Gain Therapeutics by 83.6% during the fourth quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company’s stock valued at $212,000 after purchasing an additional 44,750 shares during the period. Marshall Wace LLP bought a new position in Gain Therapeutics during the fourth quarter valued at approximately $198,000. Finally, Northern Trust Corp lifted its position in Gain Therapeutics by 88.2% during the fourth quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock valued at $183,000 after purchasing an additional 39,642 shares during the period. Hedge funds and other institutional investors own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.